Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merus N.V. filings document the company's oncology-antibody business, common-share capital structure, and completed acquisition process involving Genmab. The record includes Form 8-K material-event disclosures for the transaction agreement and completion of an acquisition or disposition of assets, along with disclosures concerning shareholder voting matters, governance matters, and capital-structure changes.
The company’s Form 15-12G records the termination of registration of Merus N.V. common shares under Section 12(g) and suspension of Exchange Act reporting duties under Sections 13 and 15(d). It identifies the common shares with €0.09 nominal value per share, reports zero holders of record as of the certification date, and shows Merus B.V. acting as successor to Merus N.V.
Merus N.V. has filed a Schedule 14D-9C describing materials related to a proposed acquisition of Merus by Genmab A/S through a tender offer by Genmab’s wholly owned subsidiary, Genmab Holding II B.V., under a Transaction Agreement dated September 29, 2025. The tender offer for Merus common shares has not yet commenced, and any offer to buy will be made only through a formal Schedule TO filing with the SEC.
Merus plans to file a Schedule 14D-9 recommendation statement and a proxy statement on Schedule 14A for an extraordinary general meeting where shareholders will vote on resolutions tied to the proposed transactions. The communication urges investors to read the tender offer documents, recommendation statement and proxy statement in full when available because they will contain the terms and conditions of the transactions. It also includes extensive forward-looking statement cautions highlighting risks such as failure to obtain sufficient tenders or approvals, competing offers, business disruption, and potential shareholder litigation. Exhibits include FAQs for employees and corrected FAQs for investors dated October 3, 2025.
Genmab A/S, through its wholly owned subsidiary Genmab Holding II B.V., plans a cash tender offer for all issued and outstanding common shares of Merus N.V., each with a nominal value of €0.09, under a Transaction Agreement dated September 29, 2025. The offer has not yet commenced and this communication serves only as advance notice, not an offer to purchase or a solicitation to sell.
Once the tender offer begins, Genmab and its subsidiary will file a detailed tender offer statement on Schedule TO, and Merus will respond with a Schedule 14D-9 recommendation statement and a proxy statement for an extraordinary general meeting to vote on related resolutions. The communication also outlines extensive forward-looking risk factors, including possible failure to obtain regulatory and shareholder approvals, potential termination of the agreement, integration challenges, unexpected costs, and broader market, clinical, and operational uncertainties.
Merus N.V. entered a Transaction Agreement with Genmab A/S and its subsidiary Genmab Holding II B.V. dated September 29, 2025 under which Merus will become an indirect wholly owned subsidiary of Genmab following certain back‑end reorganization transactions and a subsequent closing.
At Genmab's request, Merus will delist its common shares from the Nasdaq Stock Market and deregister the shares under the Exchange Act, ending its reporting obligations. The agreement provides that any Merus option with an exercise price per share below the offer consideration will vest at the acceptance time and be converted into a cash payment equal to the difference between the offer price and the exercise price multiplied by the underlying shares; options with exercise prices equal to or above the offer consideration will be cancelled for no consideration.
Parent intends to make the acquisition via a tender offer to be filed on Schedule TO; Merus will file a Schedule 14D-9 and a definitive proxy on Schedule 14A for an extraordinary general meeting. The filing cites Merus SEC filings including the Form 10-K for year ended December 31, 2024 (filed Feb 27, 2025) and a Form 10-Q for period ended June 30, 2025 as sources of risk factors and updated information.
Commodore Capital LP and Commodore Capital Master LP reported beneficial ownership of 3,525,000 common shares of Merus N.V. (CUSIP N5749R100), equal to 4.7% of the 75,565,138 shares outstanding used for the calculation. The filing shows shared voting power and shared dispositive power over all 3,525,000 shares and no sole voting or dispositive power. The Firm (Commodore Capital LP) is the investment manager to Commodore Capital Master LP, and Michael Kramarz and Robert Egen Atkinson are the managing partners who exercise investment discretion. The filing includes a certification that the shares were not acquired to change or influence control of Merus.
Merus N.V. (Common Stock, CUSIP N5749R100) is the subject of a Schedule 13G/A filed by Wellington entities reporting aggregate beneficial ownership of 3,726,723 shares, representing 5.01% of the class. The filing shows shared voting power of 3,358,050 shares and shared dispositive power of 3,726,723 shares, with no sole voting or dispositive power reported. The securities are owned of record by clients of Wellington's investment advisers and are described as held in the ordinary course of business; the filing certifies they were not acquired to change or influence control of the issuer.